Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
What analysis led to Novo Nordisk's shares falling?
Novo Nordisk's shares fell after a data analysis published in JAMA Internal Medicine showed that Eli Lilly's obesity treatment, Mounjaro, led to faster and greater weight loss compared to Novo Nordisk's Wegovy. The analysis examined health records and pharmacy dispensing data of over 9,000 patients taking each drug, finding Mounjaro to be more effective in achieving weight loss milestones.
Which drug did the analysis find more effective for weight loss?
The analysis found that Eli Lilly's drug Mounjaro (tirzepatide) led to faster and greater weight loss compared to Novo Nordisk's drug Ozempic (semaglutide). Patients taking Mounjaro were more likely to lose at least 5%, 10%, and 15% of their body weight compared to those taking Ozempic. However, it is important to note that no head-to-head clinical trial has been completed yet to directly compare the two weight-loss drugs.
Where was the comparative analysis published?
The comparative analysis was published in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro and Zepbound - and semaglutide - the main ingredient in Wegovy and Ozempic.